Lars K Munck
Overview
Explore the profile of Lars K Munck including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
278
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Miehlke S, Guagnozzi D, Zabana Y, Tontini G, Fiehn A, Wildt S, et al.
United European Gastroenterol J
. 2021 Feb;
PMID: 33619914
Introduction: Microscopic colitis is a chronic inflammatory bowel disease characterised by normal or almost normal endoscopic appearance of the colon, chronic watery, nonbloody diarrhoea and distinct histological abnormalities, which identify...
3.
Course of Disease in Patients with Microscopic Colitis: A European Prospective Incident Cohort Study
Verhaegh B, Munch A, Guagnozzi D, Wildt S, Cebula W, Diac A, et al.
J Crohns Colitis
. 2021 Jan;
15(7):1174-1183.
PMID: 33433605
Background And Aims: The disease course of microscopic colitis [MC] is considered chronic but benign. However, this assumption is based on mainly retrospective studies, reporting on incomplete follow-up of selective...
4.
Davidson S, Sjoberg K, Engel P, Lo Rinc E, Fiehn A, Vigren L, et al.
Scand J Gastroenterol
. 2018 Jun;
53(7):818-824.
PMID: 29852792
Objective: The significantly higher incidence rates of microscopic colitis (MC) in Denmark compared to Sweden remains unexplained. Methods: Consecutive patients with newly diagnosed MC in the neighbouring regions of Skåne...
5.
Wildt S, Munck L, Becker S, Brockstedt H, Bonderup O, Hitz M
Postgrad Med
. 2018 Feb;
130(3):348-354.
PMID: 29460653
Objectives: Patients with microscopic colitis (MC) have several risk factors for osteoporosis. The prevalence of osteopenia and osteoporosis in MC is unknown. The primary purpose of this study was to...
6.
Steenholdt C, Brynskov J, Thomsen O, Munck L, Christensen L, Pedersen G, et al.
J Crohns Colitis
. 2015 Aug;
9(11):1032-42.
PMID: 26245216
Background: This study assessed the effects of infliximab (IFX) treatment failure on patient-reported outcomes and explored the influence of using personalized treatment in this situation. Methods: Sixty-nine Crohn's disease patients...
7.
Steenholdt C, Brynskov J, Thomsen O, Munck L, Fallingborg J, Christensen L, et al.
Dig Dis Sci
. 2015 Feb;
60(9):2762-70.
PMID: 25673037
Background: In Crohn's disease patients failing infliximab therapy, interventions defined by an algorithm based on infliximab and anti-infliximab antibody measurements have proven more cost-effective than intensifying the infliximab regimen. Aim:...
8.
Steenholdt C, Bendtzen K, Brynskov J, Thomsen O, Munck L, Christensen L, et al.
J Crohns Colitis
. 2015 Jan;
9(3):238-45.
PMID: 25576753
Background And Aims: Intensification of the infliximab (IFX) regimen is recommended if the treatment effect is inadequate. However, the rationale for this is not well defined as the underlying mechanisms...
9.
Munck L, Hansen K, Molbak A, Balle H, Kongsgren S
Dan Med J
. 2014 May;
61(5):A4817.
PMID: 24814735
Introduction: Medication reconciliation improves congruence in cross sectional patient courses. Our regional electronic medical record (EMR) integrates the shared medication record (SMR) which provides full access to current medication and...
10.
Nielsen O, Munck L
Nat Clin Pract Gastroenterol Hepatol
. 2007 Mar;
4(3):160-70.
PMID: 17339853
Sulfasalazine and mesalazine (also known as mesalamine; 5-aminosalicylic acid) preparations have for many years been used for the treatment of IBD (i.e. ulcerative colitis and Crohn's disease), for both active...